Literature DB >> 21620785

Mycobacterium avium subsp paratuberculosis--incidences in milk and milk products, their isolation, enumeration, characterization, and role in human health.

Ami Patel1, Nihir Shah.   

Abstract

Mycobacterium avium subsp paratuberculosis (MAP), excreted in the feces and milk, is reported to be not easily inactivated by pasteurization and thermal treatments as other bacteria infecting humans and animals do. The D values of all MAP strains tested were considerably higher than those published for other pathogens. Culturing techniques for this organism are labor intensive. Although an increasing amount of scientific evidence suggests that this organism can be responsible for at least some cases of Crohn's disease (CD), there is controversy about MAP being a cause of CD in humans. In general, although some studies have described an association between the presence of MAP and CD, the role of Mycobacterium species and MAP in the etiology of this human disease remains unestablished. Although published reports indicate that it may not be completely inactivated by pasteurization of milk, the effectiveness of increasing the time or temperature in the pasteurization process has not been established and hence any potential benefit to human health cannot be determined. This article summarizes the incidences of MAP in milk and milk products with respect to human health and brief discussion of various serological as well as molecular techniques used for their isolation, enumeration, and characterization.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 21620785     DOI: 10.1016/j.jmii.2011.04.009

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  7 in total

1.  'Nano-immuno test' for the detection of live Mycobacterium avium subspecies paratuberculosis bacilli in the milk samples using magnetic nano-particles and chromogen.

Authors:  Manju Singh; Shoor Vir Singh; Saurabh Gupta; Kundan Kumar Chaubey; Bjorn John Stephan; Jagdip Singh Sohal; Manali Dutta
Journal:  Vet Res Commun       Date:  2018-04-26       Impact factor: 2.459

2.  Rapid and sensitive method to identify Mycobacterium avium subsp. paratuberculosis in cow's milk by DNA methylase genotyping.

Authors:  Silvia Leonor Mundo; Liliana Rosa Gilardoni; Federico José Hoffman; Osvaldo Jorge Lopez
Journal:  Appl Environ Microbiol       Date:  2012-12-28       Impact factor: 4.792

3.  Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment.

Authors:  Nair Nazareth; Fernando Magro; Rui Appelberg; Jani Silva; Daniela Gracio; Rosa Coelho; José Miguel Cabral; Candida Abreu; Guilherme Macedo; Tim J Bull; Amélia Sarmento
Journal:  Med Microbiol Immunol       Date:  2015-02-22       Impact factor: 3.402

4.  Anti-Mycobacterium paratuberculosis (MAP) therapy for Crohn's disease: an overview and update.

Authors:  Sailish Honap; Emma Johnston; Gaurav Agrawal; Bahij Al-Hakim; John Hermon-Taylor; Jeremy Sanderson
Journal:  Frontline Gastroenterol       Date:  2020-07-28

5.  Exploring the potential hazard of Mycobacterium avium subspecies paratuberculosis as a cause for Crohn's disease.

Authors:  Sukumar Bharathy; Lakshmanasami Gunaseelan; Kannan Porteen
Journal:  Vet World       Date:  2017-04-28

6.  Mycobacterium avium subsp. paratuberculosis lipophilic antigen causes Crohn's disease-type necrotizing colitis in Mice.

Authors:  Eiichi Momotani; Hiroshi Ozaki; Masatoshi Hori; Shizuo Yamamoto; Takashi Kuribayashi; Shigetoshi Eda; Masahiro Ikegami
Journal:  Springerplus       Date:  2012-11-08

7.  Lactase persistence, NOD2 status and Mycobacterium avium subsp. paratuberculosis infection associations to Inflammatory Bowel Disease.

Authors:  Natalia Elguezabal; Susana Chamorro; Elena Molina; Joseba M Garrido; Ander Izeta; Luis Rodrigo; Ramón A Juste
Journal:  Gut Pathog       Date:  2012-06-28       Impact factor: 4.181

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.